Prelude Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,184
| Closed | -$728K | – | 1178 |
|
|
2025
Q4 | $728K | Buy |
+3,184
| New | +$725K | 0.05% | 401 |
|
|
2025
Q2 | – | Sell |
-8,282
| Closed | -$1.74M | – | 979 |
|
|
2025
Q1 | $1.74M | Buy |
+8,282
| New | +$1.61M | 0.13% | 174 |
|
|
2024
Q4 | – | Sell |
-5,566
| Closed | -$1.1M | – | 1180 |
|
|
2024
Q3 | $1.1M | Buy |
+5,566
| New | +$1.04M | 0.07% | 360 |
|
|
2022
Q3 | – | Sell |
-2,526
| Closed | -$387K | – | 1543 |
|
|
2022
Q2 | $387K | Sell |
2,526
-136
| -5% | -$20.8K | 0.01% | 935 |
|
|
2022
Q1 | $432K | Sell |
2,662
-3,736
| -58% | -$543K | 0.01% | 922 |
|
|
2021
Q4 | $866K | Buy |
+6,398
| New | +$756K | 0.02% | 692 |
|
|
2021
Q3 | – | Sell |
-23,730
| Closed | -$2.67M | – | 1674 |
|
|
2021
Q2 | $2.67M | Buy |
+23,730
| New | +$2.67M | 0.08% | 213 |
|
|
2021
Q1 | – | Sell |
-1,880
| Closed | -$201K | – | 1503 |
|
|
2020
Q4 | $201K | Sell |
1,880
-10,251
| -85% | -$985K | 0.01% | 1117 |
|
|
2020
Q3 | $1.06M | Buy |
+12,131
| New | +$1.14M | 0.05% | 266 |
|
|
2019
Q2 | – | Sell |
-26,783
| Closed | -$2.11M | – | 1606 |
|
|
2019
Q1 | $2.16M | Buy |
26,783
+15,827
| +144% | +$1.29M | 0.12% | 163 |
|
|
2018
Q4 | $1.01M | Buy |
+10,956
| New | +$963K | 0.07% | 318 |
|
|
2018
Q2 | – | Sell |
-346
| Closed | -$33K | – | 1617 |
|
|
2018
Q1 | $33K | Sell |
346
-6,544
| -95% | -$719K | ﹤0.01% | 1184 |
|
|
2017
Q4 | $666K | Buy |
+6,890
| New | +$649K | 0.05% | 344 |
|
|
2017
Q3 | – | Sell |
-7,422
| Closed | -$538K | – | 1583 |
|
|
2017
Q2 | $538K | Buy |
7,422
+6,807
| +1,107% | +$458K | 0.05% | 319 |
|
|
2017
Q1 | $40K | Buy |
+615
| New | +$38.7K | ﹤0.01% | 1093 |
|
|
2016
Q4 | – | Sell |
-2,061
| Closed | -$130K | – | 1509 |
|
|
2016
Q3 | $130K | Buy |
+2,061
| New | +$133K | 0.01% | 728 |
|
|
2016
Q2 | – | Sell |
-9,125
| Closed | -$521K | – | 1546 |
|
|
2016
Q1 | $521K | Sell |
9,125
-2,572
| -22% | -$143K | 0.07% | 299 |
|
|
2015
Q4 | $693K | Buy |
11,697
+905
| +8% | +$52.1K | 0.11% | 216 |
|
|
2015
Q3 | $587K | Buy |
10,792
+4,051
| +60% | +$264K | 0.09% | 246 |
|
|
2015
Q2 | $453K | Sell |
6,741
-16,611
| -71% | -$1.08M | 0.06% | 337 |
|
|
2015
Q1 | $1.37M | Buy |
+23,352
| New | +$1.41M | 0.19% | 131 |
|
Other funds holding ABBV
Prelude Capital Management's ABBV Position: Q1 2026 in Review
Prelude Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 3,184 shares — an estimated $728K sold.
Prelude Capital Management first reported a position in ABBV in Q1 2015 and held it in 21 quarters. The position peaked at $2.67M in Q2 2021. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Prelude Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 3,184 AbbVie shares in Q1 2026, an estimated $728K.
- Prelude Capital Management first reported a position in AbbVie in Q1 2015 and held it in 21 quarters.
- Prelude Capital Management's AbbVie position peaked at $2.67M in Q2 2021.
- 4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.